Bridgeway Capital Management, LLC Logic Bio Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.29 - $0.67 $4,640 - $10,720	-16,000 Reduced 22.89%	53,900 $15,000
Q2 2022 Aug 15, 2022	SELL	$0.35 - $0.74 $3,500 - $7,400	-10,000 Reduced 12.52%	69,900 $25,000
Q1 2022 May 16, 2022	SELL	$0.61 - $2.49 $26,230 - $107,070	-43,000 Reduced 34.99%	79,900 $54,000
Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.53 $117,920 - $242,808	-53,600 Reduced 30.37%	122,900 $284,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $5.09 $385,000 - $509,000	100,000 Added 130.72%	176,500 $808,000
Q2 2021 Aug 16, 2021	SELL	$4.03 - $7.57 $429,195 - $806,205	-106,500 Reduced 58.2%	76,500 $340,000
Q1 2021 May 17, 2021	BUY	$6.8 - $9.16 $670,480 - $903,176	98,600 Added 116.82%	183,000 $1.33 Million
Q3 2020 Nov 16, 2020	SELL	$5.41 - $9.45 $238,040 - $415,799	-44,000 Reduced 34.27%	84,400 $766,000
Q2 2020 Aug 14, 2020	BUY	$4.25 - $8.46 $487,475 - $970,362	114,700 Added 837.23%	128,400 $1.09 Million
Q1 2020 May 15, 2020	BUY	$4.06 - $11.0 $55,621 - $150,700	13,700 New	13,700 $68,000

Ticker LOGC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,962,700
Description
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.